GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Conduit Pharmaceuticals Inc (NAS:CDT) » Definitions » Shares Outstanding (EOP)

CDT (Conduit Pharmaceuticals) Shares Outstanding (EOP) : 0.96 Mil (As of Sep. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Conduit Pharmaceuticals Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Conduit Pharmaceuticals's shares outstanding for the quarter that ended in Sep. 2024 was 0.96 Mil.

Conduit Pharmaceuticals's quarterly shares outstanding increased from Jun. 2024 (0.74 Mil) to Sep. 2024 (0.96 Mil). It means Conduit Pharmaceuticals issued new shares from Jun. 2024 to Sep. 2024 .

Conduit Pharmaceuticals's annual shares outstanding increased from Dec. 2022 (0.72 Mil) to Dec. 2023 (0.74 Mil). It means Conduit Pharmaceuticals issued new shares from Dec. 2022 to Dec. 2023 .


Conduit Pharmaceuticals Shares Outstanding (EOP) Historical Data

The historical data trend for Conduit Pharmaceuticals's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Conduit Pharmaceuticals Shares Outstanding (EOP) Chart

Conduit Pharmaceuticals Annual Data
Trend Dec21 Dec22 Dec23
Shares Outstanding (EOP)
0.72 0.72 0.74

Conduit Pharmaceuticals Quarterly Data
Dec21 Mar22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.73 0.74 0.74 0.74 0.96

Competitive Comparison of Conduit Pharmaceuticals's Shares Outstanding (EOP)

For the Biotechnology subindustry, Conduit Pharmaceuticals's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Conduit Pharmaceuticals's Shares Outstanding (EOP) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Conduit Pharmaceuticals's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Conduit Pharmaceuticals's Shares Outstanding (EOP) falls into.



Conduit Pharmaceuticals Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Conduit Pharmaceuticals  (NAS:CDT) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Conduit Pharmaceuticals Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of Conduit Pharmaceuticals's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


Conduit Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
4995 Murphy Canyon Road, Suite 300, San Diego, CA, USA, 92123
Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being, prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.
Executives
Andrew Regan director, 10 percent owner LE MANOIR DE LURIN, SAINT BARTHELEMY Z0 97133
Intelmed Llc other: See Responses 11421 GOLDEN EAGLE COURT, NAPLES FL 34120
Jennifer Isacoff Mcnealey director C/O CODEX DNA, INC., 9535 WAPLES STREET, SUITE 100, SAN DIEGO Z4 92121
David Tapolczay director, officer: Chief Executive Officer 32 CROUCH HALL LANE, ST. ALBANS X0 AL3 7EU
Faith L. Charles director ABEONA THERAPEUTICS INC., 1330 AVENUE OF THE AMERICAS - FLOOR 33, NEW YORK NY 10019
Algo Holdings, Inc. 10 percent owner, other: See Responses 100 W. CYPRESS CREEK ROAD, STE. 640, FORT LAUDERDALE NY 33309
Corvus Capital Ltd. 10 percent owner, other: See Responses WILLOW HOUSE, CRICKET SQUARE PO BOX 709, GRAND CAYMAN E9 KY1 - 1107
Freda C Lewis-hall director C/O VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY STREET, CAMBRIDGE MA 02139
James Bligh director 38 OXBERRY AVENUE, LONDON X0 SW6 5SS
Shaolin Capital Management Llc 10 percent owner 230 NW 24TH STREET, SUITE 603, MIAMI FL 33127
Richard Edward Feinberg director 2855 FIFTH AVENUE, UNIT 405, SAN DIEGO CA 92103
Murphy Canyon Acquisition Sponsor, Llc 10 percent owner 4995 MURPHY CANYON ROAD, SUITE 300, SAN DIEGO CA 92123
Chele Chiavacci Farley director 4 RIDGE ROAD, TUXEDO PARK NY 10987
Bentzen Edwin H Iv officer: Chief Accounting Officer 2513 BIRCH HOLLOW ST, HENDERSON NV 89044
Jack Kendrick Heilbron director, officer: CEO, President, and Chairman 16433 BRONCO LANE, POWAY CA 92064